Biotech Rewind Therapeutics secures financing for oral remyelination program
The lead program is an oral GPR17 antagonist intended to restore myelin in multiple sclerosis.
Rewind Therapeutics Issuer
Intelligence
The deal
- Type
- Funding
- Amount
- Not recorded
- Status
- Announced
- Round
- additional financing
- Valuation
- Not recorded
- Region
- Belgium
- Date
- 6 October 2026
As of this development: a later development may record new terms.
Lifecycle
- Announced
- Closed
The parties
Rewind Therapeutics Issuer
Activity